


# PRODUCT INFORMATION



## Dalbavancin Item No. 21161

**CAS Registry No.:** 171500-79-1  
**Formal Name:** 5,31-dichloro-38-de(methoxycarbonyl)-7-demethyl-19-deoxy-56-O-[2-deoxy-2-[(10-methyl-1-oxoundecyl)amino]-β-D-glucopyranuronosyl]-38-[[[3-(dimethylamino)propyl]amino]carbonyl]-42-O-α-D-mannopyranosyl-N<sup>15</sup>-methylristomycin A aglycone

**Synonyms:** BI 397, MDL 63397  
**MF:** C<sub>88</sub>H<sub>100</sub>Cl<sub>2</sub>N<sub>10</sub>O<sub>28</sub> (for B<sub>0</sub>)  
**FW:** 1,816.7  
**Purity:** ≥95% (mixture of A<sub>0</sub>, A<sub>1</sub>, B<sub>0</sub>, B<sub>1</sub>, B<sub>2</sub>)  
**UV/Vis.:** λ<sub>max</sub>: 281 nm  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

## Laboratory Procedures

Dalbavancin is supplied as a solid. A stock solution may be made by dissolving the dalbavancin in the solvent of choice, which should be purged with an inert gas. Dalbavancin is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of dalbavancin in these solvents is approximately 5 and 1 mg/ml, respectively.

Dalbavancin is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, dalbavancin should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Dalbavancin has a solubility of approximately 0.16 mg/ml in a 1:5 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

## Description

Dalbavancin is a semisynthetic glycopeptide antibiotic.<sup>1</sup> It inhibits the growth of Gram-positive bacteria *in vitro*, including *S. pneumoniae*, *S. pyogenes*, vancomycin-sensitive *Enterococcus* species, and various methicillin-resistant staphylococci (MIC<sub>50</sub>s = 0.03, ≤0.002, 0.13, and 0.03-0.13 mg/L, respectively). Dalbavancin increases survival in mouse models of infection with *S. aureus* and *S. pneumoniae* (ED<sub>50</sub>s = 0.08 and 0.56 mg/kg, respectively). This product is a mixture of five closely related components, dalbavancin A<sub>0</sub>, A<sub>1</sub>, B<sub>0</sub>, B<sub>1</sub>, and B<sub>2</sub>, with dalbavancin B<sub>0</sub> being the major component (≥75%). Formulations containing dalbavancin have been used in the treatment of bacterial skin infections caused by Gram-positive bacteria.

## Reference

1. Candiani, G., Abbondi, M., Borgonovi, M., *et al.* In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. *J. Antimicrob. Chemother.* **44**(2), 179-192 (1999).

**WARNING**  
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

**SAFETY DATA**  
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

**WARRANTY AND LIMITATION OF REMEDY**  
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/01/2022

## CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM